Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community: A 4-year follow-up

Alessia Buglioni, Valentina Cannone, S Jeson Sangaralingham, Denise M. Heublein, Christopher G. Scott, Kent R Bailey, Richard J. Rodeheffer, Riccardo Sarzani, John C Jr. Burnett

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background-We recently reported that normal aldosterone levels are associated with cardiovascular, renal, and metabolic disease in a sample of the US general community (Visit 1). For the current analyses we used the same cohort in a new 4-year follow-up study (Visit 2). Methods and Results-We measured aldosterone at Visit 1 and analyzed its predictive role for new diseases at Visit 2 (n=1140). We measured aldosterone at Visit 2 and investigated its associations with disease at Visit 2 (n=1368). We analyzed aldosterone continuously and we also dichotomized the variable as whether subjects were in the third tertile versus second and first tertiles. As continuous variable at Visit 1, aldosterone predicted new onset hypertension (HTN) (OR=1.36, CI=1.13-1.63, P=0.001), central obesity (OR=1.36, CI=1.07-1.73, P=0.011), and use of lipid-lowering drugs (OR=1.25, CI=1.05-1.48, P=0.012) at Visit 2, after adjustment for age, sex, and body mass index. When in the third tertile (8.5-88.6 ng/dL), aldosterone predicted type 2 diabetes (T2DM, OR=1.96, CI=1.03-3.70, P=0.039). At Visit 2, aldosterone remained associated with HTN, obesity, and chronic kidney disease (CKD), as reported for Visit 1. However, aldosterone was not associated with heart failure (HF) at Visit 1 and 2, nor was aldosterone a predictor of HF between visits. Conclusions-Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.

Original languageEnglish (US)
Article numbere002505
JournalJournal of the American Heart Association
Volume4
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Metabolic Diseases
Aldosterone
Cardiovascular Diseases
Kidney
Hypertension
Abdominal Obesity
Heart Failure
Chronic Renal Insufficiency
Obesity
Lipids
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Body Mass Index

Keywords

  • Aldosterone
  • Diabetes mellitus
  • General community
  • Heart failure
  • Obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community : A 4-year follow-up. / Buglioni, Alessia; Cannone, Valentina; Sangaralingham, S Jeson; Heublein, Denise M.; Scott, Christopher G.; Bailey, Kent R; Rodeheffer, Richard J.; Sarzani, Riccardo; Burnett, John C Jr.

In: Journal of the American Heart Association, Vol. 4, No. 12, e002505, 01.12.2015.

Research output: Contribution to journalArticle

@article{c7c6656f5be6495a91a322837a365788,
title = "Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community: A 4-year follow-up",
abstract = "Background-We recently reported that normal aldosterone levels are associated with cardiovascular, renal, and metabolic disease in a sample of the US general community (Visit 1). For the current analyses we used the same cohort in a new 4-year follow-up study (Visit 2). Methods and Results-We measured aldosterone at Visit 1 and analyzed its predictive role for new diseases at Visit 2 (n=1140). We measured aldosterone at Visit 2 and investigated its associations with disease at Visit 2 (n=1368). We analyzed aldosterone continuously and we also dichotomized the variable as whether subjects were in the third tertile versus second and first tertiles. As continuous variable at Visit 1, aldosterone predicted new onset hypertension (HTN) (OR=1.36, CI=1.13-1.63, P=0.001), central obesity (OR=1.36, CI=1.07-1.73, P=0.011), and use of lipid-lowering drugs (OR=1.25, CI=1.05-1.48, P=0.012) at Visit 2, after adjustment for age, sex, and body mass index. When in the third tertile (8.5-88.6 ng/dL), aldosterone predicted type 2 diabetes (T2DM, OR=1.96, CI=1.03-3.70, P=0.039). At Visit 2, aldosterone remained associated with HTN, obesity, and chronic kidney disease (CKD), as reported for Visit 1. However, aldosterone was not associated with heart failure (HF) at Visit 1 and 2, nor was aldosterone a predictor of HF between visits. Conclusions-Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.",
keywords = "Aldosterone, Diabetes mellitus, General community, Heart failure, Obesity",
author = "Alessia Buglioni and Valentina Cannone and Sangaralingham, {S Jeson} and Heublein, {Denise M.} and Scott, {Christopher G.} and Bailey, {Kent R} and Rodeheffer, {Richard J.} and Riccardo Sarzani and Burnett, {John C Jr.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1161/JAHA.115.002505",
language = "English (US)",
volume = "4",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community

T2 - A 4-year follow-up

AU - Buglioni, Alessia

AU - Cannone, Valentina

AU - Sangaralingham, S Jeson

AU - Heublein, Denise M.

AU - Scott, Christopher G.

AU - Bailey, Kent R

AU - Rodeheffer, Richard J.

AU - Sarzani, Riccardo

AU - Burnett, John C Jr.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background-We recently reported that normal aldosterone levels are associated with cardiovascular, renal, and metabolic disease in a sample of the US general community (Visit 1). For the current analyses we used the same cohort in a new 4-year follow-up study (Visit 2). Methods and Results-We measured aldosterone at Visit 1 and analyzed its predictive role for new diseases at Visit 2 (n=1140). We measured aldosterone at Visit 2 and investigated its associations with disease at Visit 2 (n=1368). We analyzed aldosterone continuously and we also dichotomized the variable as whether subjects were in the third tertile versus second and first tertiles. As continuous variable at Visit 1, aldosterone predicted new onset hypertension (HTN) (OR=1.36, CI=1.13-1.63, P=0.001), central obesity (OR=1.36, CI=1.07-1.73, P=0.011), and use of lipid-lowering drugs (OR=1.25, CI=1.05-1.48, P=0.012) at Visit 2, after adjustment for age, sex, and body mass index. When in the third tertile (8.5-88.6 ng/dL), aldosterone predicted type 2 diabetes (T2DM, OR=1.96, CI=1.03-3.70, P=0.039). At Visit 2, aldosterone remained associated with HTN, obesity, and chronic kidney disease (CKD), as reported for Visit 1. However, aldosterone was not associated with heart failure (HF) at Visit 1 and 2, nor was aldosterone a predictor of HF between visits. Conclusions-Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.

AB - Background-We recently reported that normal aldosterone levels are associated with cardiovascular, renal, and metabolic disease in a sample of the US general community (Visit 1). For the current analyses we used the same cohort in a new 4-year follow-up study (Visit 2). Methods and Results-We measured aldosterone at Visit 1 and analyzed its predictive role for new diseases at Visit 2 (n=1140). We measured aldosterone at Visit 2 and investigated its associations with disease at Visit 2 (n=1368). We analyzed aldosterone continuously and we also dichotomized the variable as whether subjects were in the third tertile versus second and first tertiles. As continuous variable at Visit 1, aldosterone predicted new onset hypertension (HTN) (OR=1.36, CI=1.13-1.63, P=0.001), central obesity (OR=1.36, CI=1.07-1.73, P=0.011), and use of lipid-lowering drugs (OR=1.25, CI=1.05-1.48, P=0.012) at Visit 2, after adjustment for age, sex, and body mass index. When in the third tertile (8.5-88.6 ng/dL), aldosterone predicted type 2 diabetes (T2DM, OR=1.96, CI=1.03-3.70, P=0.039). At Visit 2, aldosterone remained associated with HTN, obesity, and chronic kidney disease (CKD), as reported for Visit 1. However, aldosterone was not associated with heart failure (HF) at Visit 1 and 2, nor was aldosterone a predictor of HF between visits. Conclusions-Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.

KW - Aldosterone

KW - Diabetes mellitus

KW - General community

KW - Heart failure

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84991521643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991521643&partnerID=8YFLogxK

U2 - 10.1161/JAHA.115.002505

DO - 10.1161/JAHA.115.002505

M3 - Article

C2 - 26702078

AN - SCOPUS:84991521643

VL - 4

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 12

M1 - e002505

ER -